# Cancer Venous Thromboembolism (VTE)

> **NCT02073682** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 1046 (actual)

## Conditions studied

- Venous Thromboembolism (VTE)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Cancer

## Interventions

- **DRUG:** Edoxaban
- **DRUG:** Dalteparin
- **DRUG:** Low molecular weight heparin

## Key facts

- **NCT ID:** NCT02073682
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-16
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 1046 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073682, "Cancer Venous Thromboembolism (VTE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02073682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*